玻璃體腔內(nèi)注射貝伐單抗對(duì)增生性糖尿病視網(wǎng)膜病變玻璃體手術(shù)的影響

1、玻璃體腔內(nèi)注射貝伐單抗對(duì)增生性糖尿病視網(wǎng)膜病變玻璃體手術(shù)的影響【摘要】 目的：評(píng)估術(shù)前1wk玻璃體腔內(nèi)注射貝伐單抗對(duì)增生性糖尿病視網(wǎng)膜病變(PDR)玻璃體手術(shù)(PPV)的效果。方法：對(duì)46例PDR患者進(jìn)行回顧性研究，46例患者隨機(jī)分為玻璃體手術(shù)(PPV)組(n=28)和IVB組(n=18, PPV術(shù)前注射貝伐單抗)。玻璃體術(shù)前1wk注射貝伐單抗，比較兩組間視力，醫(yī)源性視網(wǎng)膜裂孔發(fā)生率，術(shù)中和術(shù)后出血情況。結(jié)果：術(shù)后1mo，PPV組和IVB組視力都明顯提高(82.1%對(duì)88.9%)(P<0.01)，兩組間并無明顯差異。醫(yī)源性視網(wǎng)膜裂孔發(fā)生率PPV組18例，IVB組4例(64.3%對(duì)

2、22.2%)(P<0.05)。術(shù)中出血PPV組28例，IVB組7例(100%對(duì)39%)(P<0.01)，術(shù)后出血PPV組9例，IVB組0例(32.1%對(duì)0)(P<0.01)。結(jié)論：術(shù)前注射貝伐單抗可以減少增生性糖尿病視網(wǎng)膜病變玻璃體手術(shù)中醫(yī)源性視網(wǎng)膜裂孔、術(shù)中出血和術(shù)后出血發(fā)生率。 【關(guān)鍵詞】 貝伐單抗;血管內(nèi)皮細(xì)胞生長(zhǎng)因子;增生性糖尿病視網(wǎng)膜病變;玻璃體切除手術(shù)INTRODUCTIONNonclearing vitreous haemorrhage, preretinal fibrovascular membrane and tractional r

3、etinal detachment are major causes of severe vision decrease in patients with proliferative diabetic retinopathy (PDR)1. Vitrectomy is generally used to remove vitreous haemorrhage and preretinal fibrovascular membranes and relief of vitreoretinal traction. Intraoperative bleeding and iatrogenic ret

4、inal breaks were the main complications during surgery of removing preretinal fibrovascular membrane in PDR2. Intraoperative bleeding interferes with fundus examination, detection of iatrogenic retinal breaks, performing laser therapy and leads to timeconsuming surgery. Ghost cell glaucoma and posto

5、perative bleeding are main consequences of this complication3.Bevacizumab (Avastin), a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) was approved by the US Food and Drug Administration (FDA) for the treatment for metastatic colorectal cancer. Recent reports on the

6、 intravitreal bevacizumab (IVB) injection showed promise for targeting VEGFimplicated intraocular neovascularization seen in agerelated macular degeneration and proliferative diabetic retinopathy (PDR)4. It has been recently shown to enhance the clearance of vitreous hemorrhage and induce involution

7、 of retinal neovascularization and anterior segment neovascularization with no reported complications and has been used in the treatment of proliferative diabetic retinopathy (PDR) and other retinal vascular diseases4,5. The purpose of this study is to evaluate the effect of intravitreal bevacizumab

8、 (IVB) injection before vitrectomy in PDR patients.MATERIALS AND METHODSParticipants and Grouping Preoperative evaluation included blood hypertension, blood glucose, bestcorrected visual acuity (BCVA), slitlamp, gonioscopy, ultrasonography and fundus fluorescein angiography (FFA). The surgical indic

9、ation included preretinal fibrovascular membrane involving or threatening the macula, unclearing vitreous hemorrhage of at least 1 month, vitreous hemorrhage with rubeosis iridis, massive preretinal bleeding covering the posterior pole and BCVA of 0.12 or worse. Patients with pregnancy, history of h

10、aemodialysis, history of IVB injection and vitrectomy, BCVA of 0.15 or better were excluded.Fortysix PDR patients undergoing pars plana vitrectomy (PPV) were divided into 2 groups; PPV group (28 patients, 28 eyes) undergoing PPV from Jan. 2006 to Jun. 2008 and IVB group (18 patients, 18 eyes) underg

11、oing PPV with preoperative IVB injection from July 2008 to Jun. 2009. The age of the patients in PPV group ranged between 34 and 60 years with a mean of 43±12 years; 12 patients (42.9%) were male and 16 (57.1%) were female. The age of the patients in IVB group ranged between 36 and 58 years wit

12、h a mean of 42±9 years; 10 patients (55.6%) were male and 8(44.4%) were female. BCVA of all cases was less than 0.12. All cases had type 2 diabetes mellitus and had not previous panretinal photocoagulation(PRP) treatment.This study was approved by the local research committee. All patients sign

13、ed a consent form before the study.Surgical Interventions Bevacizumab was injected 7 days prior to surgery. 1.5mg(0.06mL) of bevacizumab(100mg/4mL; Genentech, South San Francisco, California) was injected into the vitreous cavity using a 26gauge needle, 3.54mm posterior to the inferotemporal limbus

14、after topical anaesthetic administration under sterile conditions.Standard 3port pars plana vitrectomy (PPV) using 20G vitrectomy systems (Bausch & Lomb, USA). Preretinal fibrovascular membranes were removed using different techniques including membrane peeling, segmentation, delamination an

15、d en bloc dissection. PRP was done at the end of surgery. No internal limiting membrane peeling was done in any of the surgeries. The internal tamponade used was decided intraoperatively, either air or silicone oil (silicone oil was used if any multiple retinal break occurred during fibrovascular ti

16、ssue dissection).Patients were examined after 1 day, 1 week, and 1 month postsurgery.Statistical Analysis Values were expressed as mean±standard deviation. Software used was SPSS 10.0. P<0.05 was considered statistically significant.RESULTSPPV Group Bestcorrected visual acuity of 1 month

17、 after surgery showed improvement in 23 cases (82.1%), stabilized in 1 cases (3.6%) and deteriorated in 4 eye (14.3%). The mean final visual acuity reached 0.12. Six cases (21.4%) reached 0.5 or better.Intraoperative bleeding was encountered in all cases. Iatrogenic retinal breaks were reported in 1

18、8 cases (64.3%). Gas was used in 3 cases (10.7%) and silicone oil in 15 cases (53.6%). Postoperative bleeding was reported in 9 eyes (32.1%); 3 cases of them were during the first one postoperative week and 1 occurred 1 month after PPV. Seven cases cleared spontaneously within 13 weeks without treat

19、ment and 1 case was performed repeat surgery.IVB Group Final visual acuity showed improvement in 16 cases (88.9%), no change in 2 cases (11.1%). The mean final visual acuity reached 0.15. Eight cases (44.4%) reached 0.5 or better. The difference in the mean visual acuity between the two groups was n

20、ot statistically significant (P>0.05).Intraocular bleeding was encountered in 7 cases (100% in PPV group and 39% in IVB group, P<0.01). Iatrogenic breaks occurred in 4 cases (64.3% in PPV group and 22.2% in IVB group, P<0.05). Silicone oil was used in these 4 cases (22.2%). Post

21、operative bleeding was reported none in IVB group (32.1% in PPV group and 0 in IVB group,P<0.01).DISCUSSIONVEGF has been shown to contribute significantly to proliferative diabetic retinopathy. Retinal ischemia leads to an increased production of intravitreal VEGF by pigment epithelial cells,

22、 pericytes and endothelial cells. Inhibition of VEGF activity such as IVB and panretinal photocoagulation may decrease VEGF levels and inhibit retinal neovascularization. Bevacizumab can induce regression of retinal neovascularization in diabetic patients and AMD patients6,7. The effects of bevacizu

23、mab in patients with retinal neovascularization secondary to diabetic retinopathy have been evaluated in a number of studies. In a study by Averyl8, fluorescein angiography revealed reduction of leakage from the foci of neovascularization within 1 week after IVB in 45 eyes with PDR. Moradian et al9

24、reported regression of the neovascularization in eyes with active progressive PDR.Our current study revealed the efficacy of IVB in reducing the rate of iatrogenic breaks, intraocular and postoperative bleeding after vitrectomy in PDR patients. In this study, we found that IVB was helpful in quietin

25、g down the fibrovascular proliferation before vitrectomy, making surgery easier. In PPV group, 18 cases of iatrogenic breaks and 10 cases of multiple breaks were reported. It was often observed the presence of strong adhesion between the fibrovascular membranes and the retina. This leads to higher i

26、ncidence of retinal iatrogenic breaks due to difficulty in peeling the clotted blood that adhered tightly to the retina. It was also difficult to completely remove the vitreous cortex around the breaks when the iatrogenic breaks occurred. The residual vitreous cortex in the iatrogenic break area may

27、 exert strong tractional force to the retina causing the retinal breaks to enlarge into bigger hole after vitrectomy. Only 4 cases in which iatrogenic breaks occurred in IVB group may reveal that IVB quiets down the fibrovascular proliferation and makes membranepeeling easier. Hence, IVB reduced the

28、 rate of iatrogenic break and repeat surgery. Our result was supported by findings from Ishikawa et al2 who reported IVB 7 days before PPV reduced the risk of increasing tissue traction due to excessive fibrosis in patients with severe PDR and tractional retinal detachment. It also demonstrated that

29、 there were decreased surgical time and less intraoperative bleeding in patients who received IVB 5 to 7 days before vitrectomy10.【摘要】 目的：評(píng)估術(shù)前1wk玻璃體腔內(nèi)注射貝伐單抗對(duì)增生性糖尿病視網(wǎng)膜病變(PDR)玻璃體手術(shù)(PPV)的效果。方法：對(duì)46例PDR患者進(jìn)行回顧性研究，46例患者隨機(jī)分為玻璃體手術(shù)(PPV)組(n=28)和IVB組(n=18, PPV術(shù)前注射貝伐單抗)。玻璃體術(shù)前1wk注射貝伐單抗，比較兩組間視力，醫(yī)源性視網(wǎng)膜裂孔發(fā)生率，術(shù)中和術(shù)后出血

30、情況。結(jié)果：術(shù)后1mo，PPV組和IVB組視力都明顯提高(82.1%對(duì)88.9%)(P<0.01)，兩組間并無明顯差異。醫(yī)源性視網(wǎng)膜裂孔發(fā)生率PPV組18例，IVB組4例(64.3%對(duì)22.2%)(P<0.05)。術(shù)中出血PPV組28例，IVB組7例(100%對(duì)39%)(P<0.01)，術(shù)后出血PPV組9例，IVB組0例(32.1%對(duì)0)(P<0.01)。結(jié)論：術(shù)前注射貝伐單抗可以減少增生性糖尿病視網(wǎng)膜病變玻璃體手術(shù)中醫(yī)源性視網(wǎng)膜裂孔、術(shù)中出血和術(shù)后出血發(fā)生率。 【關(guān)鍵詞】 貝伐單抗;血管內(nèi)皮細(xì)胞生長(zhǎng)因子;增生性糖尿病視網(wǎng)膜病變;玻璃體切

31、除手術(shù)INTRODUCTIONNonclearing vitreous haemorrhage, preretinal fibrovascular membrane and tractional retinal detachment are major causes of severe vision decrease in patients with proliferative diabetic retinopathy (PDR)1. Vitrectomy is generally used to remove vitreous haemorrhage and preretinal fibro

32、vascular membranes and relief of vitreoretinal traction. Intraoperative bleeding and iatrogenic retinal breaks were the main complications during surgery of removing preretinal fibrovascular membrane in PDR2. Intraoperative bleeding interferes with fundus examination, detection of iatrogenic retinal

33、 breaks, performing laser therapy and leads to timeconsuming surgery. Ghost cell glaucoma and postoperative bleeding are main consequences of this complication3.Bevacizumab (Avastin), a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) was approved by the US Food and

34、Drug Administration (FDA) for the treatment for metastatic colorectal cancer. Recent reports on the intravitreal bevacizumab (IVB) injection showed promise for targeting VEGFimplicated intraocular neovascularization seen in agerelated macular degeneration and proliferative diabetic retinopathy (PDR)

35、4. It has been recently shown to enhance the clearance of vitreous hemorrhage and induce involution of retinal neovascularization and anterior segment neovascularization with no reported complications and has been used in the treatment of proliferative diabetic retinopathy (PDR) and other retinal va

36、scular diseases4,5. The purpose of this study is to evaluate the effect of intravitreal bevacizumab (IVB) injection before vitrectomy in PDR patients.MATERIALS AND METHODSParticipants and Grouping Preoperative evaluation included blood hypertension, blood glucose, bestcorrected visual acuity (BCVA),

37、 slitlamp, gonioscopy, ultrasonography and fundus fluorescein angiography (FFA). The surgical indication included preretinal fibrovascular membrane involving or threatening the macula, unclearing vitreous hemorrhage of at least 1 month, vitreous hemorrhage with rubeosis iridis, massive preretinal bl

38、eeding covering the posterior pole and BCVA of 0.12 or worse. Patients with pregnancy, history of haemodialysis, history of IVB injection and vitrectomy, BCVA of 0.15 or better were excluded.Fortysix PDR patients undergoing pars plana vitrectomy (PPV) were divided into 2 groups; PPV group (28 patien

39、ts, 28 eyes) undergoing PPV from Jan. 2006 to Jun. 2008 and IVB group (18 patients, 18 eyes) undergoing PPV with preoperative IVB injection from July 2008 to Jun. 2009. The age of the patients in PPV group ranged between 34 and 60 years with a mean of 43±12 years; 12 patients (42.9%) were male

40、and 16 (57.1%) were female. The age of the patients in IVB group ranged between 36 and 58 years with a mean of 42±9 years; 10 patients (55.6%) were male and 8(44.4%) were female. BCVA of all cases was less than 0.12. All cases had type 2 diabetes mellitus and had not previous panretinal photoco

41、agulation(PRP) treatment.This study was approved by the local research committee. All patients signed a consent form before the study.Surgical Interventions Bevacizumab was injected 7 days prior to surgery. 1.5mg(0.06mL) of bevacizumab(100mg/4mL; Genentech, South San Francisco, California) was injec

42、ted into the vitreous cavity using a 26gauge needle, 3.54mm posterior to the inferotemporal limbus after topical anaesthetic administration under sterile conditions.Standard 3port pars plana vitrectomy (PPV) using 20G vitrectomy systems (Bausch & Lomb, USA). Preretinal fibrovascular membrane

43、s were removed using different techniques including membrane peeling, segmentation, delamination and en bloc dissection. PRP was done at the end of surgery. No internal limiting membrane peeling was done in any of the surgeries. The internal tamponade used was decided intraoperatively, either air or

44、 silicone oil (silicone oil was used if any multiple retinal break occurred during fibrovascular tissue dissection).Patients were examined after 1 day, 1 week, and 1 month postsurgery.Statistical Analysis Values were expressed as mean±standard deviation. Software used was SPSS 10.0. P<0.

45、05 was considered statistically significant.RESULTSPPV Group Bestcorrected visual acuity of 1 month after surgery showed improvement in 23 cases (82.1%), stabilized in 1 cases (3.6%) and deteriorated in 4 eye (14.3%). The mean final visual acuity reached 0.12. Six cases (21.4%) reached 0.5 or better

46、.Intraoperative bleeding was encountered in all cases. Iatrogenic retinal breaks were reported in 18 cases (64.3%). Gas was used in 3 cases (10.7%) and silicone oil in 15 cases (53.6%). Postoperative bleeding was reported in 9 eyes (32.1%); 3 cases of them were during the first one postoperative wee

47、k and 1 occurred 1 month after PPV. Seven cases cleared spontaneously within 13 weeks without treatment and 1 case was performed repeat surgery.IVB Group Final visual acuity showed improvement in 16 cases (88.9%), no change in 2 cases (11.1%). The mean final visual acuity reached 0.15. Eight cases (

48、44.4%) reached 0.5 or better. The difference in the mean visual acuity between the two groups was not statistically significant (P>0.05).Intraocular bleeding was encountered in 7 cases (100% in PPV group and 39% in IVB group, P<0.01). Iatrogenic breaks occurred in 4 cases (64.3% in PPV

49、 group and 22.2% in IVB group, P<0.05). Silicone oil was used in these 4 cases (22.2%). Postoperative bleeding was reported none in IVB group (32.1% in PPV group and 0 in IVB group,P<0.01).DISCUSSIONVEGF has been shown to contribute significantly to proliferative diabetic retinopathy.

50、Retinal ischemia leads to an increased production of intravitreal VEGF by pigment epithelial cells, pericytes and endothelial cells. Inhibition of VEGF activity such as IVB and panretinal photocoagulation may decrease VEGF levels and inhibit retinal neovascularization. Bevacizumab can induce regress

51、ion of retinal neovascularization in diabetic patients and AMD patients6,7. The effects of bevacizumab in patients with retinal neovascularization secondary to diabetic retinopathy have been evaluated in a number of studies. In a study by Averyl8, fluorescein angiography revealed reduction of leakag

52、e from the foci of neovascularization within 1 week after IVB in 45 eyes with PDR. Moradian et al9 reported regression of the neovascularization in eyes with active progressive PDR.Our current study revealed the efficacy of IVB in reducing the rate of iatrogenic breaks, intraocular and postoperative

53、 bleeding after vitrectomy in PDR patients. In this study, we found that IVB was helpful in quieting down the fibrovascular proliferation before vitrectomy, making surgery easier. In PPV group, 18 cases of iatrogenic breaks and 10 cases of multiple breaks were reported. It was often observed the pre

54、sence of strong adhesion between the fibrovascular membranes and the retina. This leads to higher incidence of retinal iatrogenic breaks due to difficulty in peeling the clotted blood that adhered tightly to the retina. It was also difficult to completely remove the vitreous cortex around the breaks

55、 when the iatrogenic breaks occurred. The residual vitreous cortex in the iatrogenic break area may exert strong tractional force to the retina causing the retinal breaks to enlarge into bigger hole after vitrectomy. Only 4 cases in which iatrogenic breaks occurred in IVB group may reveal that IVB q

56、uiets down the fibrovascular proliferation and makes membranepeeling easier. Hence, IVB reduced the rate of iatrogenic break and repeat surgery. Our result was supported by findings from Ishikawa et al2 who reported IVB 7 days before PPV reduced the risk of increasing tissue traction due to excessiv

57、e fibrosis in patients with severe PDR and tractional retinal detachment. It also demonstrated that there were decreased surgical time and less intraoperative bleeding in patients who received IVB 5 to 7 days before vitrectomy10.Intraoperative bleeding is one of the main complications associated wit

58、h PPV in PDR11. We determined intraocular bleeding by direct observation during surgery. Intraoperative bleeding was observed in all cases of PPV group. Intraoperative bleeding interferes with fundus examination and detection of iatrogenic breaks. The removal of bleeding not only may create iatrogen

59、ic breaks, but also may extent the breaks and create much more bleeding. Often, surgery will not continue due to excessive intraoperative bleeding and there is a need to do the repeat surgery. Intraoperative bleeding also increases the risk of postoperative haemorrhage and should be avoided whenever possible. It is suggested that IVB is a good alternative to avoid haemorrhage.